On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Extended deadline (from 1 July to 31 July) 2017 for call to submit papers on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe. Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2013: Volume 18/ Issue 35 Article 1
Back to Table of Contents
Download (pdf)

Eurosurveillance, Volume 18, Issue 35, 29 August 2013
Note from the editors: Consensus paper on MLVA development, validation, nomenclature and quality control – an important step forward for molecular typing-based surveillance and outbreak investigation
  1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Citation style for this article: Eurosurveillance editorial team. Note from the editors: Consensus paper on MLVA development, validation, nomenclature and quality control – an important step forward for molecular typing-based surveillance and outbreak investigation. Euro Surveill. 2013;18(35):pii=20570. Article DOI:

Molecular methods have greatly contributed to refining classical infectious disease epidemiology by adding a new dimension to tracing the source of an outbreak.  In the last three decades, a multitude of such methods have been developed and a number of them have become firmly established in the tool set of epidemiologists, while others have become obsolete with the appearance of newer techniques. Pulsed-field gel electrophoresis (PGFE), for example, has for more than 20 years played a major role in the investigation of food-borne outbreaks. It has recently become more and more complemented by multiple-locus variable-number of tandem repeats analysis (MLVA). 

A factor contributing to the success of PGFE, besides its high discriminatory power, has been a consensus on how the method could be applied a standardised manner for food-borne pathogens, enabling investigators to compare their results with those of other laboratories. Consequently PGFE has been considered the gold standard in many epidemiological studies of bacterial pathogens causing infectious disease. The application and usefulness of MLVA in outbreak investigations and molecular surveillance is well accepted and was covered recently in papers in Eurosurveillance and other journals [1-6]. For MLVA, however, a global consensus on how to apply it in a standardised fashion had been missing and rendered inter-laboratory comparability of results difficult. In this issue we present a paper that ‘proposes an international consensus on the development, validation, nomenclature and quality control for MLVA used for molecular surveillance and outbreak detection based on a review of the current state of knowledge’ [7]. 

The consensus paper, by Nadon et al., is the final outcome from a meeting of an international working group in 2011 in Copenhagen, Denmark. Besides representatives from the European Centre for Disease Prevention and Control, Stockholm, Sweden, the Public Health Agency of Canada, Winnipeg, and the United States Centers for Disease Control and Prevention, Atlanta, the working group consisted of representatives from several European (Denmark, France, Germany, Norway, United Kingdom) and non-European national public health institutes (Japan, South Africa, Taiwan). The paper is complemented by a proof-of-concept study that shows that researchers can compare MLVA results between different laboratories through use of a set of calibration strains in each laboratory [8].

Eurosurveillance welcomes the consensus as an important step forward for molecular typing-based surveillance and global outbreak investigations and we hope that such broad high-level consensus will lead to wide adoption of the proposed method and to similar consensus meetings on new fast-developing techniques, such as whole genome sequencing.


  1. Lindstedt BA, Torpdahl M, Vergnaud G, Le Hello S, Weill FX, Tietze E, et al. Use of multilocus variable-number tandem repeat analysis (MLVA) in eight European countries, 2012. Euro Surveill. 2013;18(4):pii=20385. Available from: PMid:23369388. 
  2. Sabat AJ, Budimir A, Nashev D, Sá-Leão R, van Dijl JM, Laurent F, et al. Overview of molecular typing methods for outbreak detection and epidemiological surveillance. Euro Surveill. 2013;18(4):pii=20380. Available from:
  3. Hopkins KL, de Pinna E, Wain J. Prevalence of Salmonella enterica serovar 4,[5],12:i:- in England and Wales, 2010. Euro Surveill. 2012;17(37):pii=20275. Available from:
  4. Sobral D, Mariani-Kurkdjian P, Bingen E, Vu-Thien H, Hormigos K, Lebeau B, et al. A new highly discriminatory multiplex capillary-based MLVA assay as a tool for the epidemiological survey of Pseudomonas aeruginosa in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2012;31(9):2247-56. PMid:22327344. 
  5. Le Hello S, Brisabois A, Accou-Demartin M, Josse A, Marault M, Francart S, et al. Foodborne outbreak and nonmotile Salmonella enterica variant, France. Emerg Infect Dis. 2012;18(1):132-4. PMid:22257550. PMCid:PMC3310095.
  6. Sintchenko V, Wang Q, Howard P, Ha CW, Kardamanidis K, Musto J, et al. Improving resolution of public health surveillance for human Salmonella enterica serovar Typhimurium infection: 3 years of prospective multiple-locus variable-number tandem-repeat analysis (MLVA). BMC Infect Dis. 2012 Mar 31;12:78. doi: 10.1186/1471-2334-12-78.
  7. Nadon CA, Trees E, Ng LK, Møller Nielsen E, Reimer A, Maxwell N, et al. Development and application of MLVA methods as a tool for inter-laboratory surveillance. Euro Surveill. 2013;18(35):pii=20565. Available from:
  8. Larsson JT, Torpdahl M, MLVA working group, Møller Nielsen E. Proof-of-concept study for successful inter-laboratory comparison of MLVA results . Euro Surveill. 2013;18(35):pii=20566. Available from:

Back to Table of Contents
Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.